GSK's Single-Tablet Dual-Drug HIV Treatment Dovato Included in China's 2021 National Reimbursement Drug List

Shanghai, December 3, 2021 /PRNewswire/ -- Today, the National Healthcare Security Administration announced the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2021))" (hereinafter referred to as the National Medical Insurance Catalogue), the dual-drug HIV treatment regimen Dovato (generic name: Lamivudine and Dolutegravir Tablets) from GSK successfully made it to the list through negotiation.^[1]. As in ChinaThe FirstA complete, once-daily, single-tablet HIV dual-drug treatment regimen, which took only five months from its market launch to being included in the medical insurance.

Dovato is composed of a fixed dose of dolutegravir (50mg) and lamivudine (300mg). Dolutegravir is a second-generation HIV integrase strand transfer inhibitor that blocks HIV replication by preventing viral DNA from integrating into the genetic material of human immune cells (T-cells). Lamivudine is a nucleoside reverse transcriptase inhibitor commonly used in combination with other antiretroviral drugs for the treatment of HIV infection.^[2]. Dovato was developed by ViiV Healthcare.

Professor Taisheng Li, Director of the Infectious Diseases Society of the Chinese Medical AssociationRepresented by Dovato, the 'simplified therapy' has become a new option for HIV treatment. Compared with the traditional three-drug therapy, the simplified therapy can achieve the same efficacy while reducing drug exposure, drug-related side effects, and drug interactions.^[3]"We believe that after this innovative therapy is included in the medical insurance, it will better meet the long-term medication needs of patients, help patients access the medication, thereby enabling more HIV-infected individuals to benefit, improve their quality of life, and return to a normal life."

GSKGeneral Manager of China Prescription Drugs and Vaccines, Qi XinSaid: "The inclusion of Dovato in the National Medical Insurance Catalogue in the same year it was approved is a great source of excitement and pride for us. This means that people living with HIV in China will benefit more quickly from our more advanced and simpler treatment options. AIDS is a major public health issue faced globally, and it is also one of the strategic priorities in GSK's product pipeline and global R&D efforts. We look forward to introducing innovative HIV treatment solutions to China as soon as possible, continuously accelerating access to innovations, and contributing to China’s HIV/AIDS prevention and treatment efforts."

ViiV Global Head of Medical AffairsPerry MohammedPh.D.Stated: "We are extremely proud that Dovato has been included in China's National Reimbursement Drug List. The inclusion of Dovato in the NRDL will significantly enhance the accessibility of this innovative drug. We remain committed to developing more innovative HIV treatment options with the aim of bringing meaningful change to the lives of people living with HIV."

References

^[1]Dovato (Lamivudine and Dolutegravir Tablets) Restricted Payment Scope: As a complete treatment regimen for adult patients with type 1 human immunodeficiency virus (HIV-1) infection who have no history of antiretroviral therapy and no known resistance-associated mutations to any component of Lamivudine and Dolutegravir Tablets.
^[2]Lamivudine and Dolutegravir Tablets Product Information
^[3] /2020/unaids-data Cahn P.,Sierro Madera J., Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection – 3-year results from the GEMINI studies. Presented at HIV Glasgow 2020.

- End -